- Home
- SKYE vs CMU Comparison
SKYE vs CMU Comparison
Compare SKYE & CMU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- CMU
- Stock Information
- Founded
- SKYE 2012
- CMU 1987
- Country
- SKYE United States
- CMU United States
- Employees
- SKYE N/A
- CMU N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- CMU Investment Managers
- Sector
- SKYE Health Care
- CMU Finance
- Exchange
- SKYE Nasdaq
- CMU Nasdaq
- Market Cap
- SKYE 80.7M
- CMU 90.7M
- IPO Year
- SKYE N/A
- CMU N/A
- Fundamental
- Price
- SKYE $1.44
- CMU $3.29
- Analyst Decision
- SKYE Buy
- CMU
- Analyst Count
- SKYE 6
- CMU 0
- Target Price
- SKYE $16.60
- CMU N/A
- AVG Volume (30 Days)
- SKYE 1.7M
- CMU 82.4K
- Earning Date
- SKYE 05-09-2025
- CMU 01-01-0001
- Dividend Yield
- SKYE N/A
- CMU 4.08%
- EPS Growth
- SKYE N/A
- CMU N/A
- EPS
- SKYE N/A
- CMU 0.07
- Revenue
- SKYE N/A
- CMU N/A
- Revenue This Year
- SKYE N/A
- CMU N/A
- Revenue Next Year
- SKYE N/A
- CMU N/A
- P/E Ratio
- SKYE N/A
- CMU $47.57
- Revenue Growth
- SKYE N/A
- CMU N/A
- 52 Week Low
- SKYE $1.14
- CMU $2.78
- 52 Week High
- SKYE $17.65
- CMU $3.38
- Technical
- Relative Strength Index (RSI)
- SKYE 40.43
- CMU 31.12
- Support Level
- SKYE $1.26
- CMU $3.18
- Resistance Level
- SKYE $3.73
- CMU $3.31
- Average True Range (ATR)
- SKYE 0.34
- CMU 0.06
- MACD
- SKYE 0.04
- CMU -0.01
- Stochastic Oscillator
- SKYE 11.40
- CMU 27.50
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About CMU MFS Municipal Income Trust
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.